Clinical outcome of posterior fixation surgery in patients with vertebral metastasis of lung cancer

Igarashi,Tomoyuki; Okamoto,Keigo; Teramoto,Koji; Kaku,Ryosuke; Ishida,Keiko; Ueda,Keiko; Kawaguchi,Yo; Hori,Tetsuo; Hashimoto,Masayuki; Kitamura,Shoji; Tezuka,Noriaki; Hanaoka,Jun

doi:10.3892/mco.2017.1199

Clinical outcome of posterior fixation surgery in patients with vertebral metastasis of lung cancer

Authors:
- Tomoyuki Igarashi
- Keigo Okamoto
- Koji Teramoto
- Ryosuke Kaku
- Keiko Ishida
- Keiko Ueda
- Yo Kawaguchi
- Tetsuo Hori
- Masayuki Hashimoto
- Shoji Kitamura
- Noriaki Tezuka
- Jun Hanaoka
View Affiliations

Affiliations: Department of Surgery, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan, Department of Medical Oncology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan
Published online on: March 17, 2017 https://doi.org/10.3892/mco.2017.1199
Pages: 770-774

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vertebral metastasis of non-small-cell lung cancer (NSCLC) often leads to neurological paralysis, with deterioration of the patients' activities of daily living (ADL). Surgical treatments for the symptoms are unlikely to be recommended due to the poor prognosis of patients with advanced NSCLC. The aim of the present study was to retrospectively evaluate the clinical outcome of posterior spinal fixation surgery in patients with neurological paralysis resulting from vertebral metastasis of NSCLC. Between April, 2007 and March, 2012, 4 patients (3 men and 1 woman; median age, 56.5 years) underwent fixation surgery at the Shiga University of Medical Science Hospital (Otsu, Japan). The mean preoperative Tokuhashi and Tomita scores of the patients were high (8.25 and 7.0, respectively). However, the Frankel grade functional score and performance status of the patients improved following fixation surgery, after which all patients received chemoradiotherapy. Postoperatively, the median paralysis-free time was 41 months (range, 17‑42 months) and the median survival time was 42.5 months (range, 22‑43 months). According to the functional scores, the patients had a poor prognosis, which may have been a contraindication for fixation surgery. In these cases, however, surgical treatment improved the patients' ADL and increased the likelihood of receiving anticancer therapy, contributing to the prolongation of survival. Therefore, fixation surgery may be beneficial for patients with neurological paralysis following vertebral metastasis of advanced NSCLC.

View Figures

View References

1	Stewart BW and Wild CP: World Cancer Report. IARC; Lyon: 2014
2	Silvestri GA, Tanoue LT, Margolis ML, Barker J and Detterbeck F: American College of Chest Physicians: The noninvasive staging of non-small cell lung cancer: The guidelines. Chest. 123:(Suppl). 147S–156S. 2003. View Article : Google Scholar : PubMed/NCBI
3	Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, et al: ETOP Lungscape Investigators: Lungscape: Resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol. 9:1675–1684. 2014. View Article : Google Scholar : PubMed/NCBI
4	Wong DA, Fornasier VL and MacNab I: Spinal metastases: The obvious, the occult, and the impostors. Spine. 15:1–4. 1990. View Article : Google Scholar : PubMed/NCBI
5	Weigel B, Maghsudi M, Neumann C, Kretschmer R, Müller FJ and Nerlich M: Surgical management of symptomatic spinal metastases. Postoperative outcome and quality of life. Spine. 24:2240–2246. 1999. View Article : Google Scholar : PubMed/NCBI
6	Schaberg J and Gainor BJ: A profile of metastatic carcinoma of the spine. Spine. 10:19–20. 1985. View Article : Google Scholar : PubMed/NCBI
7	Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, et al: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 29:1125–1132. 2011. View Article : Google Scholar : PubMed/NCBI
8	Walker MP, Yaszemski MJ, Kim CW, Talac R and Currier BL: Metastatic disease of the spine: Evaluation and treatment. Clin Orthop Relat Res. 415:(Suppl). S165–S175. 2003. View Article : Google Scholar
9	Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H and Ohsaka S: Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine. 15:1110–1113. 1990. View Article : Google Scholar : PubMed/NCBI
10	Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H and Akamaru T: Surgical strategy for spinal metastases. Spine. 26:298–306. 2001. View Article : Google Scholar : PubMed/NCBI
11	Frankel HL, Hancock DO, Hyslop G, Melzak J, Michaelis LS, Ungar GH, Vernon JD and Walsh JJ: The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. I. Paraplegia. 7:179–192. 1969. View Article : Google Scholar : PubMed/NCBI
12	Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 12:6243s–6249s. 2006. View Article : Google Scholar : PubMed/NCBI
13	Tsuya A, Kurata T, Tamura K and Fukuoka M: Skeletal metastases in non-small cell lung cancer: A retrospective study. Lung Cancer. 57:229–232. 2007. View Article : Google Scholar : PubMed/NCBI
14	Deberne M, Ropert S, Billemont B, Daniel C, Chapron J and Goldwasser F: Inaugural bone metastases in non-small cell lung cancer: A specific prognostic entity? BMC Cancer. 14:4162014. View Article : Google Scholar : PubMed/NCBI
15	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
16	Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
17	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
18	Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, Audigier-Valette C, Geriniere L, Vernejoux JM and Chouaid C: Groupe Français de Pneumo-Cancérologie 0601 Team: Epidemiology and treatment costs of bone metastases from lung cancer: A French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol. 6:576–582. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hessler C, Vettorazzi E, Madert J, Bokemeyer C and Panse J: Actual and predicted survival time of patients with spinal metastases of lung cancer: Evaluation of the robustness of the Tokuhashi score. Spine. 36:983–989. 2011. View Article : Google Scholar : PubMed/NCBI
20	Aoude AA and Amiot LP: Surgical treatment of a patient with lung cancer metastasized to the spine with EGFR mutation: A case report. Int J Surg Case Rep. 3:510–512. 2012. View Article : Google Scholar : PubMed/NCBI